Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573811 | 0.95 | PLA2G2A (0.42) | PLA2G2APARP1DHODHMAP2K4KDM4E | |
| SCHEMBL3580539 | 0.85 | NR4A2 (0.40) | KDM4EABCB11MEN1KMT2AMAPT | |
| SCHEMBL3932873 | 0.81 | KDM4E (0.47) | KDM4EMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL3575594 | 0.80 | NR4A2 (0.40) | KDM4EABCB11MEN1KMT2AMAPT | |
| SCHEMBL13463018 | 0.77 | AMY1A (0.36) | PLA2G2ADHODHABCB11GAK | |
| SCHEMBL1370456 | 0.72 | MAPT (0.46) | PLA2G2APARP1MAP2K4KDM4EKMT2A | |
| SCHEMBL14354159 | 0.70 | NPSR1 (0.41) | KDM4ELMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL28514184 | 0.69 | PLA2G2A (0.42) | PLA2G2APARP1DHODHMAP2K4KDM4E | |
| SCHEMBL3281372 | 0.69 | KDM4E (0.48) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL20140437 | 0.68 | NPSR1 (0.47) | KDM4EMEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674810-B2 | 1,1-dioxo-1H-1Λ6-benzo[d]isothiazol-3-yl)-4-hydroxy-1,5-dihydro-pyrrol-2-one inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674810-B2 | 1,1-dioxo-1H-1Λ6-benzo[d]isothiazol-3-yl)-4-hydroxy-1,5-dihydro-pyrrol-2-one inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1786807-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| CN-101189230-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2008-05-28 | — | — | CN | disclosed |
| EP-1879885-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| EP-1786807-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006117306-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-09 | — | — | WO | disclosed |
| US-20060252785-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-11-09 | — | — | US | disclosed |
| WO-2006021340-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040927-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252785-A1 | Heterocyclic antiviral compounds | EIF2AK2, HAVCR2, POLR2E | PLA2G2A 3672/4885PARP1 382/4885DHODH 577/4885 |
| US-20060040927-A1 | Heterocyclic antiviral compounds | HAVCR2, POLR1A, HCCS | PLA2G2A 3173/4885PARP1 513/4885DHODH 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.